JPWO2019245448A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019245448A5 JPWO2019245448A5 JP2020570784A JP2020570784A JPWO2019245448A5 JP WO2019245448 A5 JPWO2019245448 A5 JP WO2019245448A5 JP 2020570784 A JP2020570784 A JP 2020570784A JP 2020570784 A JP2020570784 A JP 2020570784A JP WO2019245448 A5 JPWO2019245448 A5 JP WO2019245448A5
- Authority
- JP
- Japan
- Prior art keywords
- odebixibat
- vol
- constipation
- liver
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004185 liver Anatomy 0.000 claims description 15
- 238000002054 transplantation Methods 0.000 claims description 8
- 208000010643 digestive system disease Diseases 0.000 claims description 7
- 208000019423 liver disease Diseases 0.000 claims description 7
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims 20
- 238000012986 modification Methods 0.000 claims 20
- 206010010774 Constipation Diseases 0.000 claims 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims 8
- 206010008635 Cholestasis Diseases 0.000 claims 7
- 239000003613 bile acid Substances 0.000 claims 7
- 230000005855 radiation Effects 0.000 claims 7
- 201000002150 Progressive familial intrahepatic cholestasis Diseases 0.000 claims 6
- 230000007870 cholestasis Effects 0.000 claims 6
- 231100000359 cholestasis Toxicity 0.000 claims 6
- 239000013078 crystal Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 5
- 201000001493 benign recurrent intrahepatic cholestasis Diseases 0.000 claims 5
- 208000019425 cirrhosis of liver Diseases 0.000 claims 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 5
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 3
- 206010072268 Drug-induced liver injury Diseases 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 208000004622 abetalipoproteinemia Diseases 0.000 claims 3
- 210000000941 bile Anatomy 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 238000003786 synthesis reaction Methods 0.000 claims 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000029448 Chylomicron retention disease Diseases 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 201000004408 Hypobetalipoproteinemia Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000012347 Parenteral nutrition associated liver disease Diseases 0.000 claims 2
- 208000033147 Parenteral nutrition-associated cholestasis Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 231100000839 Vanishing bile duct syndrome Toxicity 0.000 claims 2
- 210000000013 bile duct Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000003167 cholangitis Diseases 0.000 claims 2
- 201000001883 cholelithiasis Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 230000007547 defect Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000000544 familial hypobetalipoproteinemia 1 Diseases 0.000 claims 2
- 230000004129 fatty acid metabolism Effects 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 230000035935 pregnancy Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 239000011877 solvent mixture Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023665 Barrett oesophagus Diseases 0.000 claims 1
- 208000019256 Benign recurrent intrahepatic cholestasis type 2 Diseases 0.000 claims 1
- 206010004637 Bile duct stone Diseases 0.000 claims 1
- 102100028282 Bile salt export pump Human genes 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 claims 1
- 201000009331 Choledocholithiasis Diseases 0.000 claims 1
- 208000032170 Congenital Abnormalities Diseases 0.000 claims 1
- 206010010317 Congenital absence of bile ducts Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000008960 Diabetic foot Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 1
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 208000005331 Hepatitis D Diseases 0.000 claims 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 101000724352 Homo sapiens Bile salt export pump Proteins 0.000 claims 1
- 101000955481 Homo sapiens Phosphatidylcholine translocator ABCB4 Proteins 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020915 Hypervitaminosis Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010023126 Jaundice Diseases 0.000 claims 1
- 101150072399 LSC1 gene Proteins 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000015924 Lithiasis Diseases 0.000 claims 1
- 206010025282 Lymphoedema Diseases 0.000 claims 1
- 206010054805 Macroangiopathy Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010051606 Necrotising colitis Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 208000030053 Opioid-Induced Constipation Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 102100039032 Phosphatidylcholine translocator ABCB4 Human genes 0.000 claims 1
- 206010063985 Phytosterolaemia Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 206010057969 Reflux gastritis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000002227 Sitosterolemia Diseases 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 102100036325 Sterol 26-hydroxylase, mitochondrial Human genes 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 201000004525 Zellweger Syndrome Diseases 0.000 claims 1
- 208000036813 Zellweger spectrum disease Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 201000001490 benign recurrent intrahepatic cholestasis 1 Diseases 0.000 claims 1
- 201000001488 benign recurrent intrahepatic cholestasis 2 Diseases 0.000 claims 1
- 208000026586 benign recurrent intrahepatic cholestasis type 1 Diseases 0.000 claims 1
- 208000006766 bile reflux Diseases 0.000 claims 1
- 201000005271 biliary atresia Diseases 0.000 claims 1
- 210000003445 biliary tract Anatomy 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 208000001088 cerebrotendinous xanthomatosis Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000008865 drug-induced hepatitis Diseases 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 208000009866 extrahepatic cholestasis Diseases 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 208000001130 gallstones Diseases 0.000 claims 1
- 230000001434 glomerular Effects 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000014101 glucose homeostasis Effects 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 201000010284 hepatitis E Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000016245 inborn errors of metabolism Diseases 0.000 claims 1
- 208000015978 inherited metabolic disease Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 208000001024 intrahepatic cholestasis Diseases 0.000 claims 1
- 230000007872 intrahepatic cholestasis Effects 0.000 claims 1
- 201000002161 intrahepatic cholestasis of pregnancy Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000002502 lymphedema Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 208000002865 osteopetrosis Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000000876 primary bile acid malabsorption Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 230000035764 nutrition Effects 0.000 description 9
- 235000016709 nutrition Nutrition 0.000 description 9
- 239000013589 supplement Substances 0.000 description 8
- 230000001079 digestive effect Effects 0.000 description 2
- 241001085768 Stereolepis gigas Species 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1850761-6 | 2018-06-20 | ||
SE1850762-4 | 2018-06-20 | ||
SE1850762 | 2018-06-20 | ||
SE1850761 | 2018-06-20 | ||
PCT/SE2019/050602 WO2019245448A1 (en) | 2018-06-20 | 2019-06-20 | Crystal modifications of odevixibat |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021528416A JP2021528416A (ja) | 2021-10-21 |
JPWO2019245448A5 true JPWO2019245448A5 (he) | 2023-09-01 |
JP7504032B2 JP7504032B2 (ja) | 2024-06-21 |
Family
ID=67138007
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020570778A Active JP7448490B2 (ja) | 2018-06-20 | 2019-06-20 | オデビキシバットの医薬製剤 |
JP2020570784A Active JP7504032B2 (ja) | 2018-06-20 | 2019-06-20 | オデビキシバットの結晶変態 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020570778A Active JP7448490B2 (ja) | 2018-06-20 | 2019-06-20 | オデビキシバットの医薬製剤 |
Country Status (22)
Country | Link |
---|---|
US (4) | US11802115B2 (he) |
EP (2) | EP3810581A1 (he) |
JP (2) | JP7448490B2 (he) |
KR (2) | KR20210024033A (he) |
CN (2) | CN112312893A (he) |
AU (2) | AU2019290338B2 (he) |
BR (2) | BR112020024461A2 (he) |
CA (2) | CA3100691A1 (he) |
CL (2) | CL2020003296A1 (he) |
CO (2) | CO2020015781A2 (he) |
CR (2) | CR20210026A (he) |
EC (2) | ECSP21000999A (he) |
IL (2) | IL279468B1 (he) |
JO (2) | JOP20200297A1 (he) |
MX (2) | MX2020013774A (he) |
NI (2) | NI202000103A (he) |
PE (2) | PE20210136A1 (he) |
PH (2) | PH12020552165A1 (he) |
SA (1) | SA520420731B1 (he) |
SG (2) | SG11202012151XA (he) |
TW (1) | TWI823954B (he) |
WO (2) | WO2019245448A1 (he) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2637668T3 (en) | 2010-11-08 | 2016-08-29 | Albireo Ab | Ibat inhibitors for the treatment of liver diseases |
JP6751020B2 (ja) | 2014-06-25 | 2020-09-02 | Eaファーマ株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
CA3100113A1 (en) | 2018-06-05 | 2019-12-12 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
WO2019245448A1 (en) * | 2018-06-20 | 2019-12-26 | Albireo Ab | Crystal modifications of odevixibat |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
JP2023504643A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
CN114761079B (zh) | 2019-12-04 | 2024-05-28 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
JP2023504644A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
CA3158276A1 (en) | 2019-12-04 | 2021-06-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
JP2023537285A (ja) | 2020-08-03 | 2023-08-31 | アルビレオ・アクチボラグ | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
WO2022101379A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
AU2021379076A1 (en) | 2020-11-12 | 2023-06-08 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
EP4255565A1 (en) | 2020-12-04 | 2023-10-11 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
WO2022166680A1 (zh) * | 2021-06-25 | 2022-08-11 | 苏州科睿思制药有限公司 | 奥德昔巴特的晶型及其制备方法和用途 |
CN113913436B (zh) * | 2021-11-18 | 2023-09-29 | 天津市肿瘤医院(天津医科大学肿瘤医院) | 逆转录转座基因l1-atp8b1及其作为肺鳞癌标志物的用途和治疗肺鳞癌的药物 |
WO2023174937A1 (en) | 2022-03-16 | 2023-09-21 | Sandoz Ag | Particles comprising non-crystalline odevixibat |
US20240173333A1 (en) | 2022-11-03 | 2024-05-30 | Albireo Ab | Treating Alagille Syndrome (ALGS) |
WO2024121431A1 (en) | 2022-12-09 | 2024-06-13 | Albireo Ab | Cocrystals of odevixibat |
Family Cites Families (191)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3539380A (en) | 1968-01-08 | 1970-11-10 | Upjohn Co | Methylcellulose and polyalkylene glycol coating of solid medicinal dosage forms |
GB1566609A (en) | 1977-03-10 | 1980-05-08 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions containing cholestyramine and alginic acid |
GB1573487A (en) | 1977-05-23 | 1980-08-28 | Bristol Myers Co | Bile acid binding composition |
DE3061586D1 (en) | 1979-04-30 | 1983-02-17 | Max Planck Gesellschaft | Pancreozymin-cholezystokinin active peptides, process for their preparation and pharmaceutical compositions containing them |
US5167965A (en) | 1987-02-09 | 1992-12-01 | The Dow Chemical Company | Palatable cholestyramine granules, tablets and methods for preparation thereof |
CA1313135C (en) | 1987-02-09 | 1993-01-26 | The Dow Chemical Company | Cholestyramine composition and process for its preparation |
US4900757A (en) | 1988-12-08 | 1990-02-13 | Merrell Dow Pharmaceuticals Inc. | Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane |
JP2800242B2 (ja) | 1989-03-30 | 1998-09-21 | 大正製薬株式会社 | 粒剤の製造方法 |
IL95574A (he) | 1989-09-09 | 1994-11-11 | Knoll Ag | תכשיר קולסטיראמין |
DE3930168A1 (de) | 1989-09-09 | 1991-03-14 | Knoll Ag | Verbesserte verabreichungsform fuer colestyramin |
GB8926639D0 (en) | 1989-11-24 | 1990-01-17 | Agricultural & Food Res | Delayed release formulations |
JP2542122B2 (ja) * | 1990-04-18 | 1996-10-09 | 旭化成工業株式会社 | 球状核、球形顆粒およびその製造方法 |
FI106800B (fi) | 1990-12-06 | 2001-04-12 | Hoechst Ag | Menetelmä uusien terapeuttisesti käyttökelpoisten dimeeristen sappihappojohdannaisten valmistamiseksi |
US5430116A (en) | 1991-12-20 | 1995-07-04 | Hoechst Aktiengesellschaft | Polymers and oligomers of bile acid derivatives, process for their preparation and their use as pharmaceuticals |
JPH05186357A (ja) | 1991-12-31 | 1993-07-27 | Shigeo Ochi | 飲食物消化分解産物吸収抑制手段 |
GB9203347D0 (en) | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
IT1257793B (it) | 1992-05-18 | 1996-02-13 | Composizione farmaceutica a base di acidi biliari in microgranuli a rilascio controllato | |
ATE217789T1 (de) | 1992-06-04 | 2002-06-15 | Smithkline Beecham Corp | Angenehm schmeckende pharmazeutische zusammensetzungen |
ES2111092T3 (es) | 1992-06-12 | 1998-03-01 | Hoechst Ag | Derivados de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos. |
US5350584A (en) | 1992-06-26 | 1994-09-27 | Merck & Co., Inc. | Spheronization process using charged resins |
ZA941003B (en) | 1993-02-15 | 1995-08-14 | Wellcome Found | Hypolipidaemic compounds |
IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
ATE195252T1 (de) | 1993-04-23 | 2000-08-15 | Novartis Erfind Verwalt Gmbh | Wirkstoffabgabevorrichtung mit gesteuerter freigabe |
TW289021B (he) | 1993-05-08 | 1996-10-21 | Hoechst Ag | |
EP0624593A3 (de) | 1993-05-08 | 1995-06-07 | Hoechst Ag | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel. |
TW289757B (he) | 1993-05-08 | 1996-11-01 | Hoechst Ag | |
TW289020B (he) | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
ZA956647B (en) | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
US5994391A (en) | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
WO1996008484A1 (en) | 1994-09-13 | 1996-03-21 | Monsanto Company | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
GB9423172D0 (en) | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
US5811388A (en) | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
AU724620B2 (en) | 1996-01-16 | 2000-09-28 | Sokol, Ronald J Dr. | Use of antioxidant agents to treat cholestatic liver disease |
DE19608592A1 (de) | 1996-03-06 | 1997-09-11 | Hoechst Ag | Antikörper zur selektiven immunologischen Bestimmung von Gallensäuren in biologischen Matrices |
DE69734100D1 (de) | 1996-03-11 | 2005-10-06 | G D Searle Llc St Louis | Benzothiepinen mit wirkung als inhibitoren des ileumgallensäuretransports und der taurocholate-aufnahme |
ATE394107T1 (de) | 1996-05-23 | 2008-05-15 | Novartis Pharma Gmbh | Vorbeugung und behandlung von kolonadenom oder kolonmikroadenom mit 6-fluorursodeoxycholsäure |
AU3940897A (en) | 1996-07-24 | 1998-02-10 | Zumtobel Staff Gmbh | Adapter for a retaining means used to secure a built-in lamp in a mounting hole,or retaining means or built-in lamp provided with such an adapter |
DE19633268A1 (de) | 1996-08-19 | 1998-02-26 | Hoechst Ag | Polymere Gallensäure-Resorptionsinhibitoren mit gleichzeitiger Gallensäure-Adsorberwirkung |
GB9704208D0 (en) | 1997-02-28 | 1997-04-16 | Glaxo Group Ltd | Chemical compounds |
IL131872A0 (en) | 1997-03-11 | 2001-03-19 | Searle & Co | Composition comprising an ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors |
DK0864582T3 (da) | 1997-03-14 | 2003-09-29 | Aventis Pharma Gmbh | Hypolidemiske 1,4-benzothiazepin-1,1-dioxider |
ES2248908T7 (es) | 1997-06-06 | 2014-11-24 | Depomed, Inc. | Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles |
US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
WO1998056757A1 (fr) | 1997-06-11 | 1998-12-17 | Sankyo Company, Limited | Derives de benzylamine |
AUPO763197A0 (en) | 1997-06-30 | 1997-07-24 | Sigma Pharmaceuticals Pty Ltd | Health supplement |
US5900233A (en) | 1997-10-16 | 1999-05-04 | Day; Charles E. | Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome |
US20030153541A1 (en) | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
BR9814300A (pt) | 1997-12-19 | 2002-02-05 | Searle & Co | Método de preparação de óxidos de tetraidrobenzotiepina enanciomericamente enriquecidos |
GB9800428D0 (en) | 1998-01-10 | 1998-03-04 | Glaxo Group Ltd | Chemical compounds |
US6346527B1 (en) | 1998-04-24 | 2002-02-12 | Fujisawa Pharmaceutical Co., Ltd. | Guanidine derivatives |
DE19825804C2 (de) | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
US6355672B1 (en) | 1998-08-07 | 2002-03-12 | Takeda Chemical Industries, Ltd. | Benzothiepin derivatives, process for the preparation of the same and uses thereof |
KR20010102965A (ko) | 1998-12-23 | 2001-11-17 | 윌리암스 로저 에이 | 심장혈관의 징후에 대한 회장 담즙산 수송 저해제 및담즙산 격리제의 병용 |
IL143938A0 (en) | 1998-12-23 | 2002-04-21 | Searle Llc | Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications |
EA200100704A1 (ru) | 1998-12-23 | 2002-02-28 | Джи.Ди.Сирл Ллс | Комбинация для применения по сердечно-сосудистым показаниям |
ATE240120T1 (de) | 1998-12-23 | 2003-05-15 | Searle Llc | Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen |
US6458851B1 (en) | 1998-12-23 | 2002-10-01 | G. D. Searle, Llc | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications |
CN1195748C (zh) | 1999-02-12 | 2005-04-06 | G.D.瑟尔有限公司 | 具有作为回肠胆汁酸转运和牛磺胆酸摄取抑制剂活性的新的1,2-苯并硫氮杂 |
DE19915420A1 (de) | 1999-04-06 | 2000-10-12 | Basf Ag | Stabilisierte Polyvinylpyrrolidon-Zubereitungen |
DE19916108C1 (de) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
SE9901387D0 (sv) | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
US6287609B1 (en) | 1999-06-09 | 2001-09-11 | Wisconsin Alumni Research Foundation | Unfermented gel fraction from psyllium seed husks |
US20020054903A1 (en) | 1999-10-19 | 2002-05-09 | Joseph Tyler | Direct compression polymer tablet core |
WO2001034570A1 (fr) | 1999-11-08 | 2001-05-17 | Sankyo Company, Limited | Derives heterocycliques azotes |
GB9927088D0 (en) | 1999-11-17 | 2000-01-12 | Secr Defence | Use of poly(diallylamine) polymers |
JP2003523336A (ja) | 2000-02-18 | 2003-08-05 | メルク エンド カムパニー インコーポレーテッド | 糖尿病及び脂質障害のためのアリールオキシ酢酸 |
SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
US6586434B2 (en) | 2000-03-10 | 2003-07-01 | G.D. Searle, Llc | Method for the preparation of tetrahydrobenzothiepines |
WO2001068096A2 (en) | 2000-03-10 | 2001-09-20 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
TWI241195B (en) | 2000-04-10 | 2005-10-11 | Shionogi & Co | Preventive agent for bile acidic diarrhea |
US6638498B2 (en) | 2000-06-30 | 2003-10-28 | Semorex Inc. | Molecularly imprinted polymers for the treatment and diagnosis of medical conditions |
US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
IL154008A0 (en) | 2000-07-28 | 2003-07-31 | Hoffmann La Roche | New pharmaceutical composition |
FR2812886B1 (fr) | 2000-08-08 | 2002-11-08 | Assist Publ Hopitaux De Paris | Depistage d'un nouveau syndrome hepatique et ses applications |
SE0003766D0 (sv) | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
WO2002053548A1 (en) | 2000-12-27 | 2002-07-11 | Banyu Pharmaceutical Co.,Ltd. | Benzothiazepine derivatives |
US6506921B1 (en) | 2001-06-29 | 2003-01-14 | Virginia Tech Intellectual Properties, Inc. | Amine compounds and curable compositions derived therefrom |
US20040077625A1 (en) | 2001-07-25 | 2004-04-22 | Tremont Samuel J. | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake |
US20040038862A1 (en) | 2001-07-30 | 2004-02-26 | Goodwin Bryan James | Identification of new therapeutic targets for modulating bile acid synthesis |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
NZ531796A (en) | 2001-09-08 | 2005-10-28 | Astrazeneca Ab | Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment of hyperlipidaemia |
CA2460330A1 (en) | 2001-09-12 | 2003-03-20 | G.D. Searle Llc | Method for the preparation of crystalline tetrahydrobenzothiepines |
MXPA04003524A (es) | 2001-11-02 | 2004-07-23 | Searle Llc | Compuestos de benzotiepina monofluorados y difluorados novedosos como inhibidores de transporte de acido biliar co-dependiente de sodio apical (asbt) y captacion de taurocolato. |
TW200300349A (en) | 2001-11-19 | 2003-06-01 | Sankyo Co | A 4-oxoqinoline derivative |
GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
GB0314079D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
SE0104334D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
JP2005518408A (ja) | 2001-12-29 | 2005-06-23 | ノボ ノルディスク アクティーゼルスカブ | 異常脂肪血症を治療するための、glp−1化合物と他の薬物との組み合わせ使用 |
GB0201850D0 (en) | 2002-01-26 | 2002-03-13 | Astrazeneca Ab | Therapeutic treatment |
US20040014806A1 (en) | 2002-03-08 | 2004-01-22 | Pharmacia Corporation | Methods and compositions for lowering levels of blood lipids |
EA200401227A1 (ru) | 2002-03-22 | 2005-04-28 | Рэнбакси Лабораториз Лимитед | Система доставки лекарства с контролируемым высвобождением, включающая правастатин |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
GB0216321D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Therapeutic treatment |
US7312208B2 (en) | 2002-08-28 | 2007-12-25 | Asahi Kasei Pharma Corporation | Quaternary ammonium compounds |
ATE531701T1 (de) | 2002-08-28 | 2011-11-15 | Asahi Kasei Pharma Corp | Neue quaternüre ammoniumverbindungen |
GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
WO2004076657A2 (en) | 2003-02-28 | 2004-09-10 | Mcgill University | Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides |
WO2004108067A2 (en) | 2003-04-03 | 2004-12-16 | Sun Pharmaceutical Industries Limited | Programmed drug delivery system |
GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
AU2008202120B2 (en) * | 2003-04-05 | 2009-12-17 | Albireo Ab | Use of an IBAT inhibitor for the treatment of prophylaxis of constipation |
AU2004281184C1 (en) | 2003-10-16 | 2012-01-12 | Techcom Group, Llc | Reduced digestible carbohydrate food having reduced blood glucose response |
KR20070026392A (ko) | 2004-02-27 | 2007-03-08 | 아사히 가세이 파마 가부시키가이샤 | 신규 벤조티아제핀 및 벤조티에핀 화합물 |
WO2005082414A2 (en) | 2004-03-02 | 2005-09-09 | Astellas Pharma Inc. | Concomitant drugs of a sulfonamide and another therapeutic agent |
EP1593671A1 (en) | 2004-03-05 | 2005-11-09 | Graffinity Pharmaceuticals AG | DPP-IV inhibitors |
US20050215882A1 (en) | 2004-03-23 | 2005-09-29 | The Regents Of The University Of Michigan | Noninvasive method to determine fat content of tissues using MRI |
TWI354569B (en) | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
US20050287178A1 (en) | 2004-06-23 | 2005-12-29 | Steed Barrie L | Diagnosis and treatment of heavy gallbladder densities |
JP4896480B2 (ja) | 2004-10-01 | 2012-03-14 | 第一三共ヘルスケア株式会社 | 陰イオン交換樹脂の粒子状組成物 |
US9149439B2 (en) | 2005-03-21 | 2015-10-06 | Sandoz Ag | Multi-particulate, modified-release composition |
US20090131395A1 (en) | 2005-05-05 | 2009-05-21 | Microbia, Inc. | Biphenylazetidinone cholesterol absorption inhibitors |
US20080193543A1 (en) | 2005-05-17 | 2008-08-14 | Brown University Research Foundation | Drug Delivery Formulations For Targeted Delivery |
US20070237818A1 (en) | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
DE102005033100B3 (de) | 2005-07-15 | 2007-01-25 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung |
DE102005033099A1 (de) | 2005-07-15 | 2007-01-18 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung |
JP5072848B2 (ja) | 2005-09-20 | 2012-11-14 | ノバルティス アーゲー | 低血糖イベントを低減するためのdpp−iv阻害剤の使用 |
US20100286122A1 (en) | 2006-04-10 | 2010-11-11 | Kevin Belyk | CGRP Antagonist Salt |
GB0607534D0 (en) | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
US8048413B2 (en) | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
DE102006053637B4 (de) | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DE102006053636B4 (de) | 2006-11-14 | 2008-09-18 | Sanofi-Aventis Deutschland Gmbh | Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung |
ATE493992T1 (de) | 2006-11-14 | 2011-01-15 | Sanofi Aventis Deutschland | Neue 1,4-benzothiepin-1,1-dioxidderivate mit verbesserten eigenschaften, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
DE102006053635B4 (de) | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
AU2008209566C1 (en) | 2007-01-19 | 2013-02-14 | Intercept Pharmaceuticals, Inc. | 23-substituted bile acids as TGR5 modulators and methods of use thereof |
ATE476176T1 (de) | 2007-03-02 | 2010-08-15 | Farnam Co Inc | Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung |
SI2200588T1 (sl) | 2007-09-25 | 2019-08-30 | Solubest Ltd. | Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo |
US9295677B2 (en) | 2008-02-26 | 2016-03-29 | Qing Bile Therapeutics Inc. | Polyhydroxylated bile acids for treatment of biliary disorders |
CA2735962A1 (en) | 2008-09-02 | 2010-04-15 | Usv Limited | Crosslinked polymers |
CA2744817C (en) | 2008-11-26 | 2020-07-07 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
US20110152204A1 (en) | 2009-12-18 | 2011-06-23 | Satiogen Pharmaceuticals, Inc. | Treatment of Obesity or Diabetes with Bile Acid Sequestrants |
AU2011219788B2 (en) | 2010-02-23 | 2015-05-14 | Da Volterra | Formulations for oral delivery of adsorbents in the gut |
JO3131B1 (ar) | 2010-04-27 | 2017-09-20 | Glaxosmithkline Llc | مركبات كيميائية |
ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
DK2637668T3 (en) | 2010-11-08 | 2016-08-29 | Albireo Ab | Ibat inhibitors for the treatment of liver diseases |
US20120114588A1 (en) | 2010-11-08 | 2012-05-10 | Albireo Ab | Ibat inhibitors for treatment of metabolic disorders and related conditions |
SG189470A1 (en) * | 2010-11-08 | 2013-05-31 | Albireo Ab | Ibat inhibitors for treatment of metabolic disorders and related conditions |
SG190433A1 (en) * | 2010-11-08 | 2013-06-28 | Albireo Ab | A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder |
US20140243281A1 (en) | 2011-10-28 | 2014-08-28 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
MX363161B (es) | 2011-10-28 | 2019-03-13 | Lumena Pharmaceuticals Inc | Inhibidores de la recirculación de ácidos biliares para el tratamiento de hipercolemia y enfermedad hepática colestásica. |
US9273085B2 (en) | 2012-05-07 | 2016-03-01 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative and use thereof for medical purposes |
KR20230152818A (ko) | 2013-03-15 | 2023-11-03 | 샤이어 휴먼 지네틱 테라피즈 인크. | 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제 |
JO3301B1 (ar) * | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
CN106456997B (zh) | 2014-02-27 | 2018-12-28 | 纽斯尔特科学公司 | 用于减少或预防肝性脂肪变性的组合物和方法 |
WO2015193788A1 (en) | 2014-06-16 | 2015-12-23 | Valpharma International S.P.A. | Formulation for oral administration containing mesalazine |
CN106573033A (zh) | 2014-06-25 | 2017-04-19 | Ea制药株式会社 | 固体制剂及其稳定化方法 |
JP6751020B2 (ja) | 2014-06-25 | 2020-09-02 | Eaファーマ株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
KR101674806B1 (ko) | 2014-10-20 | 2016-11-10 | 씨제이헬스케어 주식회사 | 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도 |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
US9684018B2 (en) | 2014-11-19 | 2017-06-20 | Texas Instruments Incorporated | Current sense circuit that operates over a wide range of currents |
KR20160061492A (ko) | 2014-11-21 | 2016-06-01 | 삼성디스플레이 주식회사 | 휴대용 먼지 센서 및 이를 이용한 휴대전화 |
CN105985254B (zh) | 2015-02-17 | 2018-03-16 | 上海中科绿碳化工科技有限公司 | 一种制备甲酰胺类化合物的方法 |
RU2750937C2 (ru) | 2016-02-09 | 2021-07-06 | Альбирео Аб | Пероральный состав холестирамина и его применение |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
ES2874669T3 (es) | 2016-02-09 | 2021-11-05 | Albireo Ab | Formulación oral de colestiramina y uso de la misma |
WO2017138876A1 (en) | 2016-02-09 | 2017-08-17 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11350844B2 (en) | 2016-11-23 | 2022-06-07 | Mayo Foundation For Medical Education And Research | System and method for generating nonalcoholic fatty liver disease activity score (NAS) using magnetic resonance elastography |
WO2019032026A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE |
JP7328207B2 (ja) | 2017-08-09 | 2023-08-16 | アルビレオ・アクチボラグ | コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用 |
AU2019232477A1 (en) | 2018-03-09 | 2020-09-10 | Elobix Ab | Process for the preparation of elobixibat |
US10428109B1 (en) | 2018-03-09 | 2019-10-01 | Elobix Ab | Process for the preparation of 1,5-benzothiazepine compounds |
CA3100113A1 (en) | 2018-06-05 | 2019-12-12 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
WO2019245448A1 (en) | 2018-06-20 | 2019-12-26 | Albireo Ab | Crystal modifications of odevixibat |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US20200046758A1 (en) | 2018-08-09 | 2020-02-13 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US20200046757A1 (en) | 2018-08-09 | 2020-02-13 | Albireo Ab | Cholestyramine pellets, oral cholestyramine formulations, and uses thereof |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
JP7504110B2 (ja) | 2019-02-06 | 2024-06-21 | アルビレオ・アクチボラグ | ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
WO2020161217A1 (en) | 2019-02-06 | 2020-08-13 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
BR112021015799A2 (pt) | 2019-02-12 | 2022-01-18 | Mirum Pharmaceuticals Inc | Métodos para aumentar o crescimento em pacientes pediátricos com doença colestática do fígado |
JP2023504644A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
CN114761079B (zh) | 2019-12-04 | 2024-05-28 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
JP2023504643A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
CA3158276A1 (en) | 2019-12-04 | 2021-06-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
JP2023537285A (ja) | 2020-08-03 | 2023-08-31 | アルビレオ・アクチボラグ | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
AU2021379076A1 (en) | 2020-11-12 | 2023-06-08 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
EP4255565A1 (en) | 2020-12-04 | 2023-10-11 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
-
2019
- 2019-06-20 WO PCT/SE2019/050602 patent/WO2019245448A1/en active Application Filing
- 2019-06-20 CA CA3100691A patent/CA3100691A1/en active Pending
- 2019-06-20 CA CA3100687A patent/CA3100687A1/en active Pending
- 2019-06-20 JP JP2020570778A patent/JP7448490B2/ja active Active
- 2019-06-20 AU AU2019290338A patent/AU2019290338B2/en active Active
- 2019-06-20 BR BR112020024461-9A patent/BR112020024461A2/pt unknown
- 2019-06-20 SG SG11202012151XA patent/SG11202012151XA/en unknown
- 2019-06-20 CR CR20210026A patent/CR20210026A/es unknown
- 2019-06-20 US US16/477,160 patent/US11802115B2/en active Active
- 2019-06-20 PE PE2020002088A patent/PE20210136A1/es unknown
- 2019-06-20 CN CN201980041077.4A patent/CN112312893A/zh active Pending
- 2019-06-20 KR KR1020217001712A patent/KR20210024033A/ko unknown
- 2019-06-20 TW TW108121584A patent/TWI823954B/zh active
- 2019-06-20 MX MX2020013774A patent/MX2020013774A/es unknown
- 2019-06-20 PE PE2020002089A patent/PE20210182A1/es unknown
- 2019-06-20 KR KR1020217001711A patent/KR20210024032A/ko unknown
- 2019-06-20 WO PCT/SE2019/050603 patent/WO2019245449A1/en active Application Filing
- 2019-06-20 CR CR20210027A patent/CR20210027A/es unknown
- 2019-06-20 MX MX2020013839A patent/MX2020013839A/es unknown
- 2019-06-20 JP JP2020570784A patent/JP7504032B2/ja active Active
- 2019-06-20 BR BR112020024479-1A patent/BR112020024479A2/pt unknown
- 2019-06-20 JO JOP/2020/0297A patent/JOP20200297A1/ar unknown
- 2019-06-20 JO JOP/2020/0299A patent/JOP20200299A1/ar unknown
- 2019-06-20 SG SG11202012170PA patent/SG11202012170PA/en unknown
- 2019-06-20 AU AU2019290337A patent/AU2019290337B2/en active Active
- 2019-06-20 EP EP19734937.6A patent/EP3810581A1/en active Pending
- 2019-06-20 EP EP19735664.5A patent/EP3810084A1/en active Pending
- 2019-06-20 CN CN201980039118.6A patent/CN112262130B/zh active Active
- 2019-07-10 US US16/508,036 patent/US10975046B2/en active Active
-
2020
- 2020-10-07 US US17/065,245 patent/US11365182B2/en active Active
- 2020-12-07 SA SA520420731A patent/SA520420731B1/ar unknown
- 2020-12-14 PH PH12020552165A patent/PH12020552165A1/en unknown
- 2020-12-15 IL IL279468A patent/IL279468B1/he unknown
- 2020-12-15 CO CONC2020/0015781A patent/CO2020015781A2/es unknown
- 2020-12-15 NI NI202000103A patent/NI202000103A/es unknown
- 2020-12-15 PH PH12020552168A patent/PH12020552168A1/en unknown
- 2020-12-15 NI NI202000104A patent/NI202000104A/es unknown
- 2020-12-15 CO CONC2020/0015772A patent/CO2020015772A2/es unknown
- 2020-12-15 IL IL279464A patent/IL279464A/he unknown
- 2020-12-18 CL CL2020003296A patent/CL2020003296A1/es unknown
- 2020-12-18 CL CL2020003295A patent/CL2020003295A1/es unknown
-
2021
- 2021-01-07 EC ECSENADI2021999A patent/ECSP21000999A/es unknown
- 2021-01-08 EC ECSENADI20211547A patent/ECSP21001547A/es unknown
-
2022
- 2022-05-13 US US17/744,429 patent/US20220281832A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2019245448A5 (he) | ||
AU2019290337B2 (en) | Crystal modifications of odevixibat | |
JPWO2019234077A5 (he) | ||
JPWO2020161217A5 (he) | ||
JPWO2020161216A5 (he) | ||
JP7504109B2 (ja) | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 | |
JP2023504644A (ja) | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 | |
JP2023504647A (ja) | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 | |
FI4069360T3 (fi) | Bentsotia(di)atsepiinin yhdisteet ja niiden käyttö sappihapon modulaattoreina | |
JP2023504643A (ja) | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 | |
JP2023537285A (ja) | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 | |
JP2022519664A (ja) | ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 | |
JPWO2019245449A5 (he) | ||
WO2021110884A1 (en) | Benzothia(di)azepine compounds and their use as bile acid modulators | |
AU2022285893A1 (en) | Benzothia(di)azepine compounds and their use as bile acid modulators | |
JPWO2021110883A5 (he) | ||
WO2022117778A1 (en) | Benzothia(di)azepine compounds and their use as bile acid modulators | |
JPWO2021110884A5 (he) | ||
JPWO2021110886A5 (he) | ||
Guixe-Muntet et al. | Novel therapeutics for portal hypertension and fibrosis in chronic liver disease | |
RU2021100905A (ru) | Кристаллические модификации одевиксибата | |
RU2020142990A (ru) | Бензотиа(ди)азепины и их применение в качестве модуляторов желчных кислот | |
RU2814570C2 (ru) | Соединения бензотиадиазепина и их применение в качестве модуляторов желчных кислот | |
RU2817535C2 (ru) | Соединения бензотиазепина и их применение в качестве модуляторов желчных кислот | |
TEIXEIRA et al. | HEPATOPATIAS CARDIOVASCULARES |